As of 2024-12-12, the EV/EBITDA ratio of Esperion Therapeutics Inc (ESPR) is 45.99. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ESPR's latest enterprise value is 785.98 mil USD. ESPR's TTM EBITDA according to its financial statements is 17.09 mil USD. Dividing these 2 quantities gives us the above ESPR EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 12.1x - 16.7x | 13.7x |
| Forward P/E multiples | 17.7x - 29.4x | 25.1x |
| Fair Price | 0.35 - 1.55 | 0.86 |
| Upside | -86.8% - -42.5% | -68.1% |
| Date | EV/EBITDA |
| 2024-12-04 | 59.72 |
| 2024-12-03 | 54.13 |
| 2024-12-02 | 51.95 |
| 2024-11-29 | 47.59 |
| 2024-11-27 | 43.81 |
| 2024-11-26 | 44.25 |
| 2024-11-25 | 44.25 |
| 2024-11-22 | 43.52 |
| 2024-11-21 | 42.80 |
| 2024-11-20 | 41.92 |
| 2024-11-19 | 41.92 |
| 2024-11-18 | 38.15 |
| 2024-11-15 | 37.71 |
| 2024-11-14 | 37.42 |
| 2024-11-13 | 39.31 |
| 2024-11-12 | 42.21 |
| 2024-11-11 | 43.52 |
| 2024-11-08 | 40.04 |
| 2024-11-07 | 37.57 |
| 2024-11-06 | 39.02 |
| 2024-11-05 | 37.71 |
| 2024-11-04 | 35.97 |
| 2024-11-01 | 36.40 |
| 2024-10-31 | 36.55 |
| 2024-10-30 | 37.86 |
| 2024-10-29 | 37.13 |
| 2024-10-28 | 37.86 |
| 2024-10-25 | 37.42 |
| 2024-10-24 | 36.84 |
| 2024-10-23 | 36.69 |
| 2024-10-22 | 37.86 |
| 2024-10-21 | 36.84 |
| 2024-10-18 | 36.55 |
| 2024-10-17 | 37.57 |
| 2024-10-16 | 37.71 |
| 2024-10-15 | 37.86 |
| 2024-10-14 | 37.28 |
| 2024-10-11 | 35.53 |
| 2024-10-10 | 34.37 |
| 2024-10-09 | 34.95 |
| 2024-10-08 | 36.98 |
| 2024-10-07 | 36.55 |
| 2024-10-04 | 38.29 |
| 2024-10-03 | 35.39 |
| 2024-10-02 | 33.35 |
| 2024-10-01 | 30.30 |
| 2024-09-30 | 30.88 |
| 2024-09-27 | 31.32 |
| 2024-09-26 | 30.74 |
| 2024-09-25 | 30.30 |